ES2752061T3 - Composición que contiene norbixina para la protección de las células del epitelio pigmentario retiniano - Google Patents

Composición que contiene norbixina para la protección de las células del epitelio pigmentario retiniano Download PDF

Info

Publication number
ES2752061T3
ES2752061T3 ES16722319T ES16722319T ES2752061T3 ES 2752061 T3 ES2752061 T3 ES 2752061T3 ES 16722319 T ES16722319 T ES 16722319T ES 16722319 T ES16722319 T ES 16722319T ES 2752061 T3 ES2752061 T3 ES 2752061T3
Authority
ES
Spain
Prior art keywords
composition
norbixin
use according
body weight
bixin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16722319T
Other languages
English (en)
Spanish (es)
Inventor
René LAFONT
Stanislas Veillet
José-Alain Sahel
Valérie Fontaine
Pierre-Paul Elena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorbonne Universite
Biophytis SA
Original Assignee
Sorbonne Universite
Biophytis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorbonne Universite, Biophytis SA filed Critical Sorbonne Universite
Application granted granted Critical
Publication of ES2752061T3 publication Critical patent/ES2752061T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
ES16722319T 2015-04-30 2016-04-28 Composición que contiene norbixina para la protección de las células del epitelio pigmentario retiniano Active ES2752061T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1553957A FR3035589B1 (fr) 2015-04-30 2015-04-30 Composition pour la protection des cellules de l'epithelium pigmentaire retinien
PCT/FR2016/051001 WO2016174360A1 (fr) 2015-04-30 2016-04-28 Composition contenant de la norbixine pour la protection des cellules de l'epithelium pigmentaire retinien

Publications (1)

Publication Number Publication Date
ES2752061T3 true ES2752061T3 (es) 2020-04-02

Family

ID=53758384

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16722319T Active ES2752061T3 (es) 2015-04-30 2016-04-28 Composición que contiene norbixina para la protección de las células del epitelio pigmentario retiniano

Country Status (15)

Country Link
US (1) US10314804B2 (enExample)
EP (1) EP3288551B1 (enExample)
JP (1) JP6660401B2 (enExample)
KR (1) KR102575312B1 (enExample)
CN (1) CN107708685B (enExample)
AU (1) AU2016256637A1 (enExample)
BR (1) BR112017023264A2 (enExample)
CA (1) CA2984405C (enExample)
ES (1) ES2752061T3 (enExample)
FR (1) FR3035589B1 (enExample)
IL (1) IL255276A0 (enExample)
MX (1) MX376021B (enExample)
PL (1) PL3288551T3 (enExample)
RU (1) RU2715889C2 (enExample)
WO (1) WO2016174360A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
CA3098868A1 (en) 2018-05-03 2019-11-07 L.E.A.F. Holdings Group Llc Carotenoid compositions and uses thereof
KR20200134935A (ko) 2019-05-24 2020-12-02 (주)비지엔케어 커큐민을 유효성분으로 포함하는 인간 망막색소상피세포 증식 개선용 약학 조성물
EP4054637A4 (en) * 2019-11-06 2023-12-20 L.E.A.F Holdings Group LLC CAROTINOID COMPOSITIONS AND USES THEREOF
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires
KR20210008884A (ko) 2021-01-08 2021-01-25 (주)비지엔케어 커큐민을 유효성분으로 포함하는 인간 망막색소상피세포 증식 개선용 조성물 및 기능성 식품 조성물
TWI894483B (zh) * 2022-08-24 2025-08-21 鼎赫生物科技股份有限公司 一種組合物用於治療眼睛疾病之醫藥品用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1154172A (fr) 1955-07-05 1958-04-03 Rollei Werke Franke Heidecke étui de protection pour appareils photographiques
WO2001085183A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and treatment of ocular disorders
CA2528718A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
EP1814540A2 (en) * 2004-11-16 2007-08-08 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
JP2008179632A (ja) * 2006-12-29 2008-08-07 Fuji Chem Ind Co Ltd 抗酸化剤
JP5550854B2 (ja) * 2009-06-10 2014-07-16 理研ビタミン株式会社 一重項酸素消去剤
FR2947173B1 (fr) 2009-06-25 2012-01-27 Inst Biophytis Composition alimentaire destinee a la protection solaire
JP2012097003A (ja) * 2010-10-29 2012-05-24 Gifu City ビキシン誘導体及び細胞保護剤
FR2975008B1 (fr) * 2011-05-13 2014-03-07 Inst Biophytis Utilisation de composes et composition pour le traitement de la degenerescence maculaire liee a l'age (dmla)

Also Published As

Publication number Publication date
CA2984405C (fr) 2024-01-23
IL255276A0 (en) 2017-12-31
PL3288551T3 (pl) 2020-04-30
CA2984405A1 (fr) 2016-11-03
JP6660401B2 (ja) 2020-03-11
FR3035589A1 (fr) 2016-11-04
JP2018518460A (ja) 2018-07-12
KR102575312B1 (ko) 2023-09-06
BR112017023264A2 (pt) 2018-08-07
RU2017141462A (ru) 2019-05-31
US20180289651A1 (en) 2018-10-11
MX2017013918A (es) 2018-04-24
AU2016256637A1 (en) 2017-12-14
EP3288551A1 (fr) 2018-03-07
US10314804B2 (en) 2019-06-11
CN107708685B (zh) 2021-09-21
RU2715889C2 (ru) 2020-03-04
EP3288551B1 (fr) 2019-07-31
WO2016174360A9 (fr) 2017-11-16
RU2017141462A3 (enExample) 2019-09-12
CN107708685A (zh) 2018-02-16
FR3035589B1 (fr) 2019-12-13
WO2016174360A1 (fr) 2016-11-03
KR20180011777A (ko) 2018-02-02
MX376021B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
ES2752061T3 (es) Composición que contiene norbixina para la protección de las células del epitelio pigmentario retiniano
Alugoju et al. Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review
KR101660195B1 (ko) 크릴 오일과 반응한 아스타잔틴 조성물 및 관련 방법
JP6432913B2 (ja) 黄斑変性症の治療のためのビクサ・オレラナ由来組成物
JP7324263B2 (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
Kang et al. Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro
JP7530950B2 (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
JP6484708B2 (ja) 網膜疾患を予防及び治療するための、有効成分としてスピルリナ・マキシマ抽出物を含有する医薬組成物
KR20120051458A (ko) 크릴 인지질을 이용하여 아스타잔틴 및 dha- 및/또는 epa-결합된 포스파티딜세린을 함유한 조성물을 제조하는 방법 및 이러한 방법에 의해 제조된 조성물
US20180207113A1 (en) Vivo intracellular reprogramming composition and method of making and using same
Morilla et al. More Than Pigments: The Potential of Astaxanthin and Bacterioruberin-Based Nanomedicines. Pharmaceutics 2023, 15, 1828
Ketsutham et al. Herb-derived Compounds and Other Potential Molecules for Non-exudative Age-related Macular Degeneration (AMD): A Systematic Review.
Gao et al. The Comparative Protective Effects of Ganoderma Spores Lipid and Fish Oil on N‐Methyl‐N‐Nitrosourea‐Induced Photoreceptor Cell Lesion in Rats
Vaibhav et al. Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer’s Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside
Banik et al. A critical insight into the physicochemical stability of macular carotenoids with respect to their industrial production, safety profile, targeted tissue delivery, and bioavailability
WO2020008359A1 (en) A formulation for the prevention and as a coadjuvant treatment of neurodegenerative diseases
CN107949382A (zh) 3‑脱氧花青素在治疗眼部疾病中的用途
Abd et al. 12 Nanotechnology Could